CEL-SCI Corp
About: CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Employees: 44
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
1.47% less ownership
Funds ownership: 10.37% [Q4 2024] → 8.9% (-1.47%) [Q1 2025]
15% less funds holding
Funds holding: 61 [Q4 2024] → 52 (-9) [Q1 2025]
29% less call options, than puts
Call options by funds: $17K | Put options by funds: $24K
37% less capital invested
Capital invested by funds: $2.75M [Q4 2024] → $1.73M (-$1.02M) [Q1 2025]
53% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 15
100% less funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for CVM.
Financial journalist opinion
Based on 3 articles about CVM published over the past 30 days
